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Background: Laparoscopic liver resection is used in specialized centers all over the world. However, laparoscopic
liver resection has never been compared with open liver resection in a prospective, randomized trial.
Methods/Design: The Oslo-CoMet Study is a randomized trial into laparoscopic versus open liver resection for the
surgical management of hepatic colorectal metastases. The primary outcome is 30-day perioperative morbidity.
Secondary outcomes include 5-year survival (overall, disease-free and recurrence-free), resection margins, recurrence
pattern, postoperative pain, health-related quality of life, and evaluation of the inflammatory response. A cost-utility
analysis of replacing open surgery with laparoscopic surgery will also be performed. The study includes all resections
for colorectal liver metastases, except formal hemihepatectomies, resections where reconstruction of vessels/bile ducts
is necessary and resections that need to be combined with ablation. All patients will participate in an enhanced
recovery after surgery program. A biobank of liver and tumor tissue will be established and molecular analysis will
be performed.
Discussion: After 35 months of recruitment, 200 patients have been included in the trial. Molecular and immunology
data are being analyzed. Results for primary and secondary outcome measures will be presented following the
conclusion of the study (late 2015). The Oslo-CoMet Study will provide the first level 1 evidence on the benefits of
laparoscopic liver resection for colorectal liver metastases.
Trial registration: The trial was registered in ClinicalTrals.gov (NCT01516710) on 19 January 2012.
Keywords: Laparoscopic liver resection, Open liver resection, Parenchyma sparing liver resection, Colorectal liver
metastases, Randomized controlled trialBackground
Colorectal cancer is the third most common cancer
worldwide [1]. In 2008 it accounted for 608,700 deaths
globally, most of whom died of metastatic tumors [1].
Surgical resection is currently considered the only cura-
tive treatment for colorectal liver metastases, with 5-year* Correspondence: aasmund@fretland.no
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58% [2-5].
There are two surgical approaches to resection of liver
tumors - open and laparoscopic. No randomized con-
trolled trial comparing the two methods has been com-
pleted, but cohort and case-matched studies found a
significantly reduced length of hospital stay and need for
postoperative opiates after laparoscopic liver resection
[6-8]. Long-term oncologic outcomes for laparoscopic
liver resection are comparable to open liver resection inl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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vational studies support these findings [12-14].
Postoperative morbidity after surgery is a major cause
of patient suffering and societal costs. The incidence of
postoperative morbidity in observational studies on
patients undergoing open liver surgery varies from 22%
to 47% [15-17], whereas for laparoscopic resection the
morbidity rate varies from 11% to 15% [18-20]. Laparo-
scopic liver resection in patients who previously have
undergone open liver resection has a morbidity rate of
29% [21].
In October 2014, the 2nd International Consensus
Conference on Laparoscopic Liver Resection was held in
Morioka, Japan [22]. At this consensus conference, lap-
aroscopic liver resection was still judged to be in the as-
sessment phase (Balliol grade 3 [23]), as the all the
existing evidence is of low quality. The jury recom-
mended that higher quality studies should be performed,
using standardized reporting of 90 days mortality and
complication rates (article in press, Annals of Surgery).
The aim of this randomized controlled trial will thus
be to determine whether laparoscopic liver resection of
colorectal liver metastases results in less postoperative
morbidity than open liver resection.
Methods/Design
Funding and ethics approval
The South-Eastern Norway Regional Health Authority
funds this study. Approval was obtained from the
Regional Committee for Health and Research Ethics
(2011/1285/REK Sør-Øst B) and from the Data Protection
Official for Research at Oslo University Hospital. The
study was registered in Clinicaltrials.gov (NCT01516710)
before recruitment started. The guidelines of Consolidated
Standards of Reporting Trials (CONSORT) statement will
be followed [24].
Study design
The Oslo-CoMet study is a prospective superiority
study. The study is powered to determine whether lap-
aroscopic liver resection of colorectal liver metastases
leads to less postoperative morbidity than open liver re-
section. In addition, the study will also compare epidural
patient-controlled analgesia to intravenous patient-
controlled analgesia in open liver resection. Patients will
be treated equally in every way except the intervention.
All patients will undergo an enhanced recovery after sur-
gery (ERAS) program.
All patients will undergo a standardized radiological
workup before inclusion, consisting of contrast-enhanced
X-ray computed tomography (CT) scans of the thorax
and abdomen, and magnetic resonance imaging of the
liver (enhanced with liver-specific contrast agent and
diffusion-weighted sequences). In cases where extra-hepatic metastases are suspected, fludeoxyglucose posi-
tron emission tomography scans will be performed. In
cases of diagnostic uncertainty, contrast-enhanced ultra-
sound will be used to increase diagnostic certainty.
Inclusion and exclusion criteria
The study will include all resections for colorectal liver
metastases, except formal hemihepatectomies, resections
where reconstruction of vessels/bile ducts is necessary
and resections that need to be combined with ablation.
At Oslo University Hospital, parenchyma sparing liver
resection is an essential part of the multimodal treatment
of liver metastases, and therefore fewer formal hemihepa-
tectomies are performed in our institution than in many
other institutions. Patients must be willing and able to give
informed consent. Exclusions include patients with pre-
vious liver ablations, patients where resection of primary
tumor is planned for the same procedure and patients
with nonresectable extrahepatic disease.
Primary and secondary endpoints
The primary endpoint of the Oslo-CoMet study is the
rate of postoperative morbidity and mortality. Morbidity
will be registered using the Accordion-classification and
the Comprehensive Complication Index during hospital
stay, at discharge and at the outpatient clinic after
30 days [25-27].
Secondary endpoints include 5-year overall, disease-
free and recurrence-free survival, recurrence pattern and
management of recurrence. Differences in the inflamma-
tory response, resection margins, hospital and societal
costs, health-related quality of life, hernia development,
postoperative pain, and intraoperative unfavorable inci-
dents (according to the modified Satava classification
[28,29]). A biobank with blood and tissue from tumor
and healthy liver will be established for molecular ana-
lyses (Figure 1).
Management of postoperative pain
The optimal management of pain following major ab-
dominal surgery is subject to on-going debate. Epidural
analgesia after open abdominal surgery has been shown
to reduce pain [30], postoperative ileus [31] and in-
flammatory response [32,33], but it also carries rare but
severe complications such as post-dural puncture
headache and paralysis of lower extremities. A recent
systematic review concludes that large-scale prospective
randomized trials are required to find the optimal man-
agement of postoperative pain after open liver resection
[34]. In our institution, postoperative epidural analgesia
is used for open liver resection, but not for laparoscopic
resection. Therefore, we decided to randomize between
epidural analgesia and intravenous opioids in the open
surgery group.
Figure 1 Oslo-CoMet study flowchart. CEA, carcinoembryonic antigen; CT, computed tomography; ERAS, Enhanced Recovery After Surgery;
p.o., postoperative; QoL, quality of life.
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pain management guided by the same standardized
protocol. The area of planned incision (either open or
trocar) will be infiltrated by local anesthesia. At the start
of the operation, 8 mg intravenous dexamethasone will
be administered, while intravenous paracetamol and
ketorolac will be administered at the end of anesthesia.
Patients in whom an epidural catheter is placed will not
receive ketorolac because of the risk of epidural
hematoma. On the day of surgery and on postoperative
days 1 and 2, the patient will receive paracetamol 1 g
6-hourly and intravenous ketorolac 30 mg 8-hourly. Fol-
lowing this, the patient will receive oral paracetamol 1 g6-hourly and oral diclofenac 50 mg 8-hourly. In the lap-
aroscopic group, and in the part of the open group not
randomized to receive epidural analgesia, a patient-
controlled analgesic pump (PCA) will deliver intraven-
ous opioid pain relief (ketobemidone) in bolus doses of
0.1 mg/kg body weight. According to unit policy, the
PCA will be discontinued as soon as possible, and pa-
tients will then be offered oral diclofenac, supplemented
by paracetamol and intravenous or oral opioids.
Enhanced recovery after surgery
The ERAS program is now an established part of peri-
operative care in many centers, and has been adapted
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length of stay after open liver resection [35], ERAS pro-
vides a framework for standardizing the perioperative
management of both treatment groups in our trial, redu-
cing bias. If a patient will need intensive care treatment,
or for other reasons is unable to follow the ERAS pro-
gram, it will be initiated as soon as the patient is well
enough.
Randomization procedure
At the outpatient clinic, patients will receive both verbal
and written information about the study. When patients
have given their written, informed consent, rando-
mization will be performed. Randomization will be gen-
erated in proportion 2:1:1 (laparoscopic resection with
intravenous analgesia: open resection with epidural anal-
gesia: open resection with intravenous analgesia). The
software used for registration of patient data will gener-
ate randomization, the details of which are available on
request. The patient will be informed about the result
of randomization upon admission to Oslo University
Hospital on the day before surgery.
Blinding
A blinded assessor will evaluate the primary endpoints
separately using the nurses’ electronic patient record
system.
Confidentiality, data handling and monitoring
Every patient will be assigned a unique, encoded number.
A designated information technology manager will control
the decoding key. Trial data will be stored on a secure ser-
ver with regular backup, and all activity on the server will
be traced. Patients can withdraw from the study at any
time without consequences, and data from these patients
will be deleted. A Data and Safety Management Board
(DSMB) will be established [37]. The DSMB consists of a
chairperson, a medical specialist and an independent
statistician, and the board will assess safety issues when
necessary.
Surgical technique
Surgical technique will be at the discretion of the opera-
ting surgeon. For open surgery, an L-shaped, subcostal
or midline incision will be used according to tumor size
and location. For laparoscopy, three ports are used ini-
tially, with addition of extra ports or, in selected cases,
hand ports as necessary.
For both open and laparoscopic surgery, parenchyma
will be divided with electrosurgical instruments, mainly
LigaSure® (Covidien, Mansfield, MA, USA), Thunderbeat®
(Olympus, Tokyo, Japan) or Cayman® (B.Braun, Melsungen,
Germany), sometimes assisted by ultrasonic aspirators,
mainly SonoSurg aspirator® (Olympus, Tokyo, Japan) andSöring aspirator® (Söring, Quickborn, Germany). En-
doscopic staplers, Endo-GIA® (Covidien) and Endopath®
(Ethicon, Bridgewater, NJ, USA), will be used for dividing
large vessels and sometimes also for parenchyma division.
When the Ligasure® is not used for this purpose, the liver
capsula will be divided with ultrasonic scissors, such as
Sonicision® (Covidien), SonoSurg scissors® (Olympus) or
Harmonic scalpel® (Ethicon).
Inflammatory response
The inflammatory response will be evaluated in the first
45 patients included in the study by measuring selected
alarmins, cytokines, chemokines and terminal comple-
ment complex in fresh frozen ethylenediaminetetraacetic
acid plasma taken before surgery, every hour during sur-
gery and at 2, 6 and 24 hours after surgery. Due to fi-
nancial limitations, it will not possible to perform this
comprehensive evaluation of the inflammatory response
on all patients in the study. Based on previous expe-
riences [38], 45 patients are considered to be sufficient
to show differences in the inflammatory response after
open and laparoscopic liver resection.
Resection margins
The operating surgeon will assess macroscopic resection
margins without slicing the specimen. Before surgery,
each tumor will be given a number, the largest being
number 1 and so on, and the resection margin will be
evaluated for every resected tumor. The final micro-
scopic margin will be measured during routine histo-
logical assessment by the histopathologist.
Hospital and societal costs
Costs for both open and laparoscopic surgery will be es-
timated alongside the clinical trial at the individual pa-
tient level, using a health care and a societal perspective.
For the initial hospital stay, both direct patient-related
activities and indirect nonpatient-related costs (overhead
costs) will be estimated. To estimate the exact resource
use in the operating theatre, we will quantify the per-
sonnel resources and the disposable and nondisposable
equipment used during surgery in a subpopulation of 50
patients. Cost drivers (complications) will be quantified
by the Accordion system [25]. Health care and societal
costs after discharge from Oslo University Hospital will
be assessed by questionnaires that the patients fill in at
the 30-day and 4-month follow-up. For resource use
after the 4-month follow-up, the Oslo-CoMet study will
be linked to national registers with data on resource use
in the health care sector at the individual patient level.
The registers include information on the use of specialist
health care (the Norwegian Patient Registry), primary
care services and services from privately practicing
physicians, specialists and psychologists (the KUHR-
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and dispensed prescription drugs (the Norwegian Pre-
scription Database).
Health-related quality of life
To assess patient health-related quality of life, patients will
fill in the short-form 36-item (SF-36) version 2.0 [39] at
baseline, and at the 30-day and 4-month follow-up. After
24 months, the SF-36 will be mailed to patients with en-
couragement to return it to Oslo University Hospital by
mail. The SF-36 includes one multi-item scale measuring
several health domains: (1) physical functioning, (2) role
limitations caused by physical health problems, (3) bodily
pain, (4) general health, (5) vitality, (6) social functioning,
(7) role limitation caused by emotional problems, and
(8) mental health. Scores per dimension range from 0 to
100; higher scores indicate better health status. SF-36 has
been translated to several languages, including Norwegian.
It has been tested for psychometric properties in several
countries, including Norway, with internal consistency
(Cronbach’s alpha) ranging from 0.80 (role emotional) to
0.93 (bodily pain) [40]. The SF-36 has previously been
used to show differences in health-related quality of life
for several surgical procedures, including laparoscopic and
open donor nephrectomy [41]. The SF-36 will also be
transformed into the SF-6D, which is a preference-based
measure of health, also referred to as utilities. This is done
by running an algorithm on 6 out of the 36 dimensions in
the SF-36. The algorithm is based on a population-based
study in the UK [42]. Utilities are measured on a 0 (dead)
to 1 (best possible health) scale [43], and will, in combi-
nation with the estimated costs of the two procedures, be
used in the cost-utility analysis in the Oslo-CoMet study.
The disease specific EORTC QLQ-30 LMC-21 [44] will be
used in a subgroup of the study patients in order to make
a comparison between the two forms. This has previously
never been performed on patients undergoing liver resec-
tion. LMC-21 will be collected at the same time points as
SF-36.
Hernia development
The incision type and length, and the port size and
number will be recorded. The incidence of incisional
hernias will be evaluated during clinical examination at
the outpatient clinic after 4 months, and using the
abdominal CT taken at oncological follow-up every
4 months thereafter.
Postoperative pain
Postoperative pain will be recorded when the patient ar-
rives at the ward from the postoperative care depart-
ment, and at 14.00 on postoperative days 1 to 5. Trained
ward nurses will perform pain registration using the vali-
dated, verbally administered 11-point Numeric RatingScale (0–10). If the patient is fully mobilized and dis-
charged before day 5, patients will perform the pain
registration themselves after receiving careful instruc-
tions from nurses. The Numeric Rating Scale is closely
correlated to the Visual Analogue Scale [45,46], and can
be easier to complete for postoperative patients as it can
be administered verbally.
Follow-up
Thirty days after surgery, participants in the Oslo-CoMet
study will meet a surgeon in the outpatient clinic for in-
spection of wounds, registration of any complications aris-
ing after discharge, review of histology and planning of
adjuvant chemotherapy. Patients will also fill in the SF-36
and a questionnaire recording resource use at the 30-day
follow-up, at 4 months and 2 years. Four months after sur-
gery, and every 4 months for the first 2 years, patients are
examined with CT scans of the thorax and abdomen,
measurement of carcinoembryonic antigen and clinical
examination by a surgeon. After 2 years, the surveillance
interval will be every 6 months until at least 5 years
or dropout. The follow-up is identical to Norwegian
guidelines.
Biobank
In this prospective randomized trial there will also be
potential for posing questions of more basic and transla-
tional nature and, for this purpose, a comprehensive bio-
bank will be generated. All specimens are transported
on ice to the pathologist directly after extraction. The
pathologist will immediately collect tissue from both
healthy liver and resected tumor. This will be done care-
fully so routine evaluation of resection margins not will
be compromised. Tissue will be snap frozen in liquid ni-
trogen and placed in an ultrafreezer (−80°C).
A systems biology approach will be taken, and from
primary tumors, normal liver tissue and blood deri-
vatives (mononuclear cells, plasma and serum), DNA,
RNA and protein extracts will be generated. A range of
molecular analyses will be performed using high through-
put array-based strategies for analysis of, for example,
genomic variation, gene expression, protein modifications
and metabolic profiles. Furthermore, formalin-fixed,
paraffin-embedded tumor tissue from routine pathology
processing will be available, and will be collected from
referring hospitals for the primary tumors to make pos-
sible the generation of tissue microarrays for comparing
characteristics of the metastatic lesions with the primary
tumors by, for instance, immunohistochemistry. Results
from all these analyses will be correlated to disease out-
come, but also with other study endpoints; for all included
patients, a comprehensive set of clinical information will
be available, allowing the investigation of prognostic and
predictive biomarkers.
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In order to extend the use of laparoscopic video, an ap-
plication for streaming to a repository will be used. The
repository is hosted on a server in the hospital enterprise
network, together with a database of the videos. The ob-
jective is to provide a streamlined platform to process
surgical videos for clinical quality control and educa-
tional purposes. The video streaming application allows
real-time tagging of events during surgery, postproce-
dure tagging and video editing to produce a short video
of highlights. A set of predefined tagging parameters for
laparoscopic liver metastasis surgery is used. The lapar-
oscopy videos will be exported to the main data collec-
tion platform of the project.
Database
The case report form (CRF) for each patient in the study
will be implemented as an XML document which will be
stored in a database. When changes are made on a CRF,
a copy of the old CRF will be stored together with a log
showing who made the changes. Users will not have ac-
cess to the CRF log. For security reasons there will beFigure 2 Oslo-CoMet study: overview of substudies and translational
emission tomography; CT, Computed Tomography.one main copy of the database with full patient identifi-
cation, and two copies with modifications: one anon-
ymized database, and one with de-identified information.
Analysis will never be performed on the main database
(Figure 2).Registry
A registry will be created of all patients who give con-
sent to participate but for some reason cannot be ran-
domized. A CONSORT flow diagram will be created
showing the total number of patients that were operated
for colorectal liver metastases in the study period, and
the reasons for all exclusions of patients that were eli-
gible for the study.Statistics
After reviewing our own data and the literature, we ex-
pect a 13% morbidity rate in the laparoscopic group
[19,47] and a 27% rate in the open group [17,19,48].
With a significance level of 5% and two-sided test, 254
patients will be needed to complete the study with 80%research. SF-36, Short Form 36; FDG-PET, fludeoxyglucose positron
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280 patients.
Descriptive statistics will be used to describe baseline
data. We will use statistical methods for contingency ta-
bles and categorical data to analyze rates and pro-
portions at single time points. Statistical analyses for
repeated measures will be used to investigate develop-
ments over time. To assess mortality, survival analysis
will be performed.
Intention-to-treat
Analysis of all patients will be performed according to
the intention-to-treat principle. However, data will also
be presented per-protocol and for the actual treatment
groups. This especially concerns converted laparoscopic
operations, where patients will cross over to the open
group. We consider it important to present also the ac-
tual treatment data, as they will be useful especially for
systematic reviewers.
Discussion
Justification of the trial
Currently only low-level evidence supports the imple-
mentation of laparoscopic liver resection over open liver
resection for the surgical management of hepatic colo-
rectal metastases. Thus, the trial is scientifically and
ethically justified.
Selection of endpoints
The primary endpoint of this study is complications
within 30 days, reported using the Accordion system
[25] and the Comprehensive Complication Index [27].
Serious complications after surgery have been shown to
influence survival for several surgical treatments, includ-
ing liver resection for colorectal metastases [17], gastric
resection for cancer [49] and pancreatoduodenectomy
for periampullary cancer [50]. However, complication
data on atypical liver resections are not easily available,
as most reported material on open liver resections in-
cludes formal and extended resections as well as atypical
resections. Thus a moderate 27% expected complication
rate for open resections [17,19,48] and 13% for laparo-
scopic resections was chosen [19,47,51,52]. In the years
prior to the study, most atypical liver resections in our
hospital were performed by laparoscopy, and currently
more than 600 laparoscopic major and minor liver resec-
tions have been performed at Oslo University Hospital.
Enhanced recovery after surgery
The optimization of perioperative care has received
much attention over the last two decades. ERAS pro-
tocols aim to attenuate stress response, thus reducing
complications, length of stay and improving patient
comfort. An ERAS protocol, which has strict guidelinesfor oral intake, use of analgesics and early mobilization,
ensures similar treatment of both groups in a surgical
randomized controlled trial. This will improve the trial
quality not only by enhancing recovery in both groups,
but by improving the performance of the control group.
The Orange II trial also follows an ERAS protocol [36].
Single center versus multicenter
The Oslo-CoMet study is a single center study from a
high volume Hepato Pancreato Biliary (HPB) laparos-
copy center. After the merger of hospitals in Oslo, our
HPB centre has solitary treatment responsibility for the
2.8 million people in the South-Eastern Norway Regional
Health Authority [53]. This allowed to us create one al-
gorithm for radiology, recruitment, surgical technique,
chemotherapy and follow-up. These advantages, together
with the lack of possible partners (there are no compar-
able laparoscopic HPB centers in the Nordic countries),
helped the study group decide that a single center study
was most suitable.
The Intervention Centre at Oslo University Hospital is
a research and development unit with long experience in
development and implementation of surgical procedures.
The centre has a framework well suited for running a
randomized controlled trial. The study is a joint venture
between the Department of HPB Surgery, Oslo University
Hospital, and the Intervention Centre, with direct fun-
ding from the South-Eastern Norway Regional Health
Authority.
Choice of resections
The study will include all liver resections less than three
segments, atypical and anatomical. Thus, there will be a
great diversity of operations included, from small wedge
resections to large parenchyma sparing resections. The
randomization is expected to equalize these differences.
This design closely reflects the reality of todays paren-
chyma sparing treatment of colorectal liver metastases
[54,55]. The Orange II plus trial, a multicenter trial of
laparoscopic versus open hemihepatectomy, is currently
recruiting patients and will supplement the scientific
picture with results of formal hepatectomies. The
Oslo-CoMet trial will also verify the safety and effect of
parenchyma sparing liver resections for colorectal liver
metastases.
Blinding
Blinding of patients for a surgical procedure can be per-
formed using large wound dressings, but the epidural
analgesia will be almost impossible to hide. We found
that adequate blinding of surgeons and nursing per-
sonnel would be virtually impossible in our department.
The reason for blinding of patients is primarily to avoid
the change of behavior in the trial [56]. As the patients
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fore surgery, we judge that possibility for change of be-
havior is small. The primary endpoint is morbidity, an
objective parameter that the patient cannot influence.
We admit, though, that the reporting of pain, quality of
life and to a certain degree the length of stay could be
influenced by the fact that the patients know which op-
eration they have had.
We still realize that lack of blinding may weaken the
study. Patients receiving their preferred treatment may
perform better than they otherwise would have, and vice
versa. Our experience is, however, that some patients
will prefer the “safe” option of open surgery while others
will prefer the “modern” laparoscopic surgery.
Trial status
As of 10 January 2015, 200 patients have been included in
the Oslo-CoMet study. The samples for the first im-
munology study have been analyzed and results will be
published shortly. The first quality of life data will be pub-
lished when 4 months follow-up of the first 120 patients is
ready. Tissue from the bio bank is being processed and
more than 50 samples have been analyzed using the Ion
Torrent® platform (Life Technologies, Grand Island, NY,
USA). Data concerning primary and secondary endpoints
will not be published until the expected number of pa-
tients is reached. No interim analysis is planned but safety
issues are continuously evaluated.
The Oslo-CoMet study (NCT01516710) will to our
knowledge be the largest randomized controlled trial on
laparoscopic versus open resection of colorectal liver me-
tastases. The Orange II (NCT00874224) and Orange II plus
(NCT01441856) trials are currently recruiting. A Chinese
(NCT01768741) and a South Korean (NCT00606385) trial
of hepatocellular carcinoma resections are also recruiting
patients. Together these trials will provide level 1 evidence
on the comparison of open and laparoscopic liver surgery.
The Oslo-CoMet study is planned to complete recruit-
ment in 2015.
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